

# Coronavirus Disease 2019 (COVID-19) Situation Report

Data as reported by national authorities by 24:00 local time 25 May 2021

Situation Report No. 260 - Kingdom of Bahrain  
26<sup>th</sup> of May, 2021



	Global		Eastern Mediterranean Region	
	COVID-19 Cases	COVID-19 Deaths	COVID-19 Cases	COVID-19 Deaths
<b>Total</b>	167,423,479	3,480,480	9,955,811	199,581
<b>New</b>	1,558,820 in 3 days	32,005 in 3 days	85,985 in 3 days	1,562 in 3 days

## Kingdom of Bahrain

	Confirmed Cases	Recovered Cases	Deaths	Active Cases	Critical Cases	PCR Tests	Vaccine First Dose	Vaccine Second Dose
	<b>Total</b>	223,613	198,220	866	24,527	193	4,529,080	888,488
<b>New</b>	8,743 in 3 days	4,883 in 3 days	57 in 3 days	-	-	60,364 in 3 days	-	-

## HIGHLIGHTS

- The Mortality were: 32 Bahraini citizens (20 male [33, 48, 50, 52, 61, 62, 62, 63, 67, 70, 72, 78, 80, 87, 90, 90, and 96 years old] and 12 female [42, 48, 50, 52, 53, 53, 63, 67, 73, 80, 83 and 85 years old]) and 25 expatriates (18 male [34, 34, 34, 38, 38, 44, 44, 52, 52, 55, 55, 56, 59, 60, 62, 70 and 78 years old] and 7 female [33, 45, 49, 53, 52 and 67 years old]).
- Increasing number of citizens and residents continue to take COVID-19 Vaccine in Bahrain; and Ministry of Health (MOH) revealed the total number of individuals vaccinated as of 22 May 2021 for the first dose (888,488) and for the second dose (732,710).
- MOH calls on all to register to get their vaccinations and booster doses.
- MOH increased daily vaccination capacity to 31,000 doses administered at 31 health centers across the Kingdom.
- Court sentenced eight defendants to six months in jail and fined them B01000 to B03000 for violating mandatory quarantine and precautionary measures for combating COVID-19. Also, nine restaurants and three salons are closed for violating the public health protocols.
- MOH provided instructions on testing positive following a rapid COVID-19 test.
- WHO: Responding to non-communicable diseases during and beyond the COVID-19 pandemic; see link below.
- WHO: Interim guidance on Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapidimmuno assay; see link below.
- WHO: Global TB progress a trisk; see link below.
- WHO: SAGE values framework for the allocation and prioritization of COVID-19 vaccination; see link below.
- WHO: Interim guidance Operational considerations for COVID-19 surveillance using GISRS; see link below.
- WHO-CMRA joint statement on the need for improved global regulatory alignment on COVID-19 medicines and vaccines; see link below.
- WHO: Interim guidance on Diagnostics, therapeutics, vaccine readiness, and other health products for COVID-19; see link below.
- WHO: Evidence to recommendations: COVID-19 mitigation in the aviation sector; see link below.
- WHO: Health workforce policy and management in the context of the COVID-19 pandemic response; see link below.
- WHO: COVID-19 vaccine introduction and deployment costing tool; see link below.
- WHO: Considerations for implementing a risk-based approach to international travel in the context of COVID-19; see link below.
- WHO: Risk assessment tool to inform mitigation measures for international travel in the context of COVID-19; see link below.
- WHO: Rational use of personal protective equipment for coronavirus disease (COVID-19) and considerations during severe shortages; see link below.
- WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access; see link below.
- WHO: Access to COVID-19 tools funding commitment tracker; see link below.
- WHO: New research highlights risks of separating newborns from mothers during COVID-19 pandemic; see link below.
- WHO Guideline Development Group Living Guidelines for COVID-19; see link below.
- WHO: What is the Access to COVID-19 Tools (ACT) Accelerator, how is it structured and how does it work?; see link below.
- Update 55 - WHO COVID-19 guideline development process; see link below.
- WHO: Draft landscape and tracker of COVID-19 candidate vaccines; see link below.
- WHO: COVAX reaches over 100 economies, 42 days after first international delivery; see link below.
- WHO-backed global youth mobilization funds young people's ideas to combat impact of COVID-19 pandemic; see link below.
- COVID-19 vaccines: Knowledge gaps and research priorities - WHO and focal consultation; see link below.
- WHO: COVID-19 Exercise Programme - Drills for Vaccine Deployment; see link below.
- WHO lists Moderna vaccine for emergency use; see link below.
- WHO: COVID-19 home care bundle for health care workers; see link below.
- WHO: Joint Note on Means to Protect Health Care from Acts of Violence in the COVID-19 Vaccination Rollout in Fragile, Conflict-affected and Vulnerable Settings; see link below.
- WHO: Taking action on COVID-19: A toolkit for selecting and enacting change strategies that improve health worker adherence to infection prevention and control measures for COVID-19 in your health facility; see link below.
- WHO lists additional COVID-19 vaccine for emergency use and issues interim policy recommendations; see link below.
- WHO: Landscape of observational study designs on the effectiveness of COVID-19 vaccination; see link below.
- WHO: Terms of Reference of the WHO COVID-19 Infection Prevention and Control Research Working Group; see link below.
- WHO: Evidence review - Public health measures in the aviation sector in the context of COVID-19: quarantine and isolation; see link below.
- WHO: Sinopharm [Vero Cell]-inactivated, COVID-19 vaccine; see link below.


## IMPORTANT LINKS

- Daily COVID-19 updates on MOH website: <https://www.moh.gov.bh/>
- WHO COVID-19 weekly situation reports: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/>
- WHO COVID-19 Dashboard: <https://covid19.who.int/>
- WHO: Responding to non-communicable diseases during and beyond the COVID-19 pandemic: <https://bit.ly/35a2u8r>
- WHO: Emergency Global Supply Chain System(COVID-19) catalogue: <https://www.who.int/publications/m/item/emergency-global-supply-chain-system-covid-19-catalogue>
- WHO: Interim guidance on Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapidimmuno assay bit.ly/3270Y7
- WHO: SAGE values framework for the allocation and prioritization of COVID-19 vaccination bit.ly/320u402
- WHO: Interim guidance Operational considerations for COVID-19 surveillance using GISRS: <https://bit.ly/347M70G>
- WHO-CMRA joint statement on the need for improved global regulatory alignment on COVID-19 medicines and vaccines bit.ly/3paw3M8
- WHO: Interim guidance on Diagnostics, therapeutics, vaccine readiness, and other health products for COVID-19: <https://www.who.int/publications/m/item/interim-guidance-on-diagnostics-therapeutics-vaccine-readiness-and-other-health-products-for-covid-19>
- WHO: Evidence to recommendations: COVID-19 mitigation in the aviation sector: <https://www.who.int/publications/m/item/evidence-to-recommendations-covid-19-mitigation-in-the-aviation-sector>
- WHO: Health workforce policy and management in the context of the COVID-19 pandemic response: <https://bit.ly/32e568d>
- COVID-19 vaccine introduction and deployment costing tool: <https://www.who.int/publications/m/item/COVID-19-vaccine-introduction-and-deployment-costing-tool>
- WHO: Considerations for implementing a risk-based approach to international travel in the context of COVID-19: <https://www.who.int/publications/m/item/WHO-2019-nCoV-Risk-based-international-travel-2020.1>
- WHO: Risk assessment tool to inform mitigation measures for international travel in the context of COVID-19: <https://www.who.int/publications/m/item/WHO-2019-nCoV-Risk-based-international-travel-2020.1>
- WHO: Rational use of personal protective equipment for coronavirus disease (COVID-19) and considerations during severe shortages: <https://www.who.int/publications/m/item/rational-use-of-personal-protective-equipment-for-coronavirus-disease-covid-19-and-considerations-during-severe-shortages>
- WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access: <https://www.who.int/news/item/21-05-2021-who-issues-validation-for-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access>
- WHO: Access to COVID-19 tools funding commitment tracker: <https://www.who.int/publications/m/item/access-to-covid-19-tools-tracker>
- WHO: New research highlights risks of separating newborns from mothers during COVID-19 pandemic: <https://www.who.int/news/item/18-05-2021-new-research-highlights-risks-of-separating-newborns-from-mothers-during-covid-19-pandemic>
- WHO Guideline Development Group Living Guidelines for COVID-19: <https://www.who.int/publications/m/item/who-guideline-development-group-living-guidelines-for-covid-19-biographies>
- WHO: What is the Access to COVID-19 Tools (ACT) Accelerator, how is it structured and how does it work?: <https://www.who.int/news/item/18-05-2021-what-is-the-access-to-covid-19-tools-act-accelerator-how-is-it-structured-and-how-does-it-work>
- Update 55 - WHO COVID-19 guideline development process: <https://www.who.int/publications/m/item/update-55-who-covid-19-guideline-development-process>
- WHO: Draft landscape and tracker of COVID-19 candidate vaccines: <https://www.who.int/publications/m/item/draft-landscape-and-tracker-of-covid-19-candidate-vaccines>
- WHO: COVAX reaches over 100 economies, 42 days after first international delivery: <https://www.who.int/news/item/08-05-2021-covax-reaches-over-100-economies-42-days-after-first-international-delivery>
- WHO-backed global youth mobilization funds young people's ideas to combat impact of COVID-19 pandemic: <https://www.who.int/news/item/25-05-2021-who-backed-global-youth-mobilization-funds-young-peoples-ideas-to-combat-impact-of-covid-19-pandemic>
- COVID-19 vaccines: Knowledge gaps and research priorities - WHO and focal consultation: <https://www.who.int/publications/m/item/covid-19-vaccines-knowledge-gaps-and-research-priorities-who-and-focal-consultation>
- WHO: COVID-19 Exercise Programme - Drills for Vaccine Deployment: <https://www.who.int/publications/m/item/who-covid-19-exercise-programme-drills-for-vaccine-deployment>
- WHO lists Moderna vaccine for emergency use: <https://www.who.int/news/item/20-05-2021-who-lists-moderna-vaccine-for-emergency-use>
- WHO: COVID-19 home care bundle for health care workers: <https://www.who.int/publications/m/item/covid-19-home-care-bundle-for-health-care-workers>
- WHO: Joint Note on Means to Protect Health Care from Acts of Violence in the COVID-19 Vaccination Rollout in Fragile, Conflict-affected and Vulnerable Settings: <https://www.who.int/publications/m/item/joint-note-on-means-to-protect-health-care-from-acts-of-violence-in-the-covid-19-vaccination-rollout-in-fragile-conflict-affected-and-vulnerable-settings>
- WHO: Taking action on COVID-19: A toolkit for selecting and enacting change strategies that improve health worker adherence to infection prevention and control measures for COVID-19 in your health facility: <https://www.who.int/publications/m/item/taking-action-on-covid-19-a-toolkit-for-selecting-and-enacting-change-strategies-that-improve-health-worker-adherence-to-infection-prevention-and-control-measures-for-covid-19-in-your-health-facility>
- WHO lists additional COVID-19 vaccine for emergency use and issues interim policy recommendations: <https://www.who.int/news/item/07-05-2021-who-lists-additional-covid-19-vaccine-for-emergency-use-and-issues-interim-policy-recommendations>
- WHO: Landscape of observational study designs on the effectiveness of COVID-19 vaccination: <https://www.who.int/publications/m/item/landscape-of-observational-study-designs-on-the-effectiveness-of-covid-19-vaccination>
- WHO: Terms of Reference of the WHO COVID-19 Infection Prevention and Control Research Working Group: <https://www.who.int/publications/m/item/terms-of-reference-of-the-who-covid-19-infection-prevention-and-control-research-working-group>
- WHO: Evidence review - Public health measures in the aviation sector in the context of COVID-19: quarantine and isolation: <https://www.who.int/publications/m/item/evidence-review-public-health-measures-in-the-aviation-sector-in-the-context-of-covid-19-quarantine-and-isolation-25-may-2021>
- WHO: Sinopharm [Vero Cell]-inactivated, COVID-19 vaccine: <https://www.who.int/publications/m/item/sinopharm-vero-cell-inactivated-covid-19-vaccine>


## IMPORTANT CONTACTS

- The National Focal Person is Dr. Najat Mohamed Abulfateh, email: [NAI@health.gov.bh](mailto:NAI@health.gov.bh)
- International Health Regulations focal person is Dr. Kubra Salman, email: [knasser@health.gov.bh](mailto:knasser@health.gov.bh)

Number of New Cases



Total Number of Cases



Number of New Deaths

